S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom

Takeda Pharmaceutical (TAK) SEC Filings & 10K Form

$13.16
-0.08 (-0.60%)
(As of 04/17/2024 ET)

Recent Takeda Pharmaceutical SEC Filings

DateFilerForm TypeView
04/15/2024
5:02 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/10/2024
5:10 AM
Phathom Pharmaceuticals, Inc. (Subject)
Takeda Pharmaceutical (Filed by)
Form SC 13D/A
04/01/2024
5:15 AM
Phathom Pharmaceuticals, Inc. (Subject)
Takeda Pharmaceutical (Filed by)
Form SC 13D/A
03/27/2024
5:34 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/09/2024
5:03 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/06/2024
8:36 AM
BlackRock Inc. (Filed by)
Takeda Pharmaceutical (Subject)
Form SC 13G/A
02/05/2024
5:24 AM
Sumitomo Mitsui Trust Holdings, Inc. (Filed by)
Takeda Pharmaceutical (Subject)
Form SC 13G/A
02/02/2024
5:16 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/01/2024
5:18 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/01/2024
5:06 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/25/2024
5:13 AM
Phathom Pharmaceuticals, Inc. (Issuer)
Takeda Pharmaceutical (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/25/2024
5:11 AM
Phathom Pharmaceuticals, Inc. (Subject)
Takeda Pharmaceutical (Filed by)
Form SC 13D/A
01/19/2024
5:03 AM
Equillium, Inc. (Subject)
Takeda Pharmaceutical (Filed by)
Form SC 13G
01/16/2024
5:01 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/14/2023
5:01 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/30/2023
5:01 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/13/2023
5:05 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/30/2023
5:02 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/26/2023
5:20 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/26/2023
5:22 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/18/2023
5:21 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/18/2023
5:20 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/02/2023
5:17 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/28/2023
5:17 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/11/2023
5:50 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/01/2023
5:10 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/27/2023
5:05 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/12/2023
5:07 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/10/2023
5:26 AM
Sequeira Ramona (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2023
5:33 AM
Bitetti Teresa Marie (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2023
5:35 AM
Takeda Pharmaceutical (Subject)
Wozniewski Thomas Otto Claus (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2023
5:16 AM
Kim Julie So-Young (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2023
5:20 AM
Duprey Lauren Rusckowski (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2023
5:22 AM
Pignagnoli Agosti Marcello (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2023
5:24 AM
Lugogo Mwana Pietrina (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2023
5:06 AM
Ricci Gabriele (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2023
5:09 AM
Plump Andrew Stewart (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2023
5:12 AM
Greco Gerard M (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2023
5:14 AM
Platford Giles Richard (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/06/2023
5:18 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/03/2023
5:02 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
Top 5 AI Stocks to Buy for 2024 (Ad)

5 Best AI Stocks to Invest In Investors are getting very rich in AI stocks right now. Wall Street legend is giving away the name and ticker of the little-known AI stock Wall Street is currently buying hand-over-fist.

Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
06/28/2023
5:35 AM
Takeda Pharmaceutical (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
06/28/2023
5:00 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/28/2023
5:02 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/28/2023
5:07 AM
Takeda Pharmaceutical (Filer)
Form 20-F
Registration statement / Annual report / Transition report  
06/23/2023
5:13 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/23/2023
5:10 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/09/2023
5:03 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/01/2023
5:02 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/30/2023
5:19 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/30/2023
5:20 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/30/2023
5:11 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/30/2023
5:14 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/26/2023
6:08 AM
Calithera Biosciences, Inc. (Issuer)
Takeda Pharmaceutical (Reporting)
Takeda Ventures, Inc. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/26/2023
6:08 AM
Calithera Biosciences, Inc. (Subject)
Takeda Pharmaceutical (Filed by)
Form SC 13D/A
05/17/2023
5:02 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/15/2023
5:09 AM
Takeda Pharmaceutical (Filer)
Form SD
Specialized Disclosure Report  
05/11/2023
5:07 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/11/2023
5:10 AM
Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)


Related Companies and Tools

This page (NYSE:TAK) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners